Red Cat Holdings, Inc. Common Stock
RCAT
$4.29
+1.90%
Red Cat Holdings is a drone technology company that integrates robotic hardware and software for military, government, and commercial operations, with a product suite spanning the Arachnid family of ISR and precision-strike drones (including the Black Widow small unmanned ISR system), the WEB (Warfighter Electronic Bridge) ground control station, the Edge 130 Blue, the Trichon fixed-wing VTOL, and FANG FPV strike drones, organized across its Teal, FlightWave, and Blue Ops divisions within the Aerospace & Defense industry. It is a small-cap, defense-tech pure play rather than a diversified prime contractor, positioning itself as a U.S.-centric challenger in the emerging market for attritable, software-defined unmanned systems aimed at Pentagon programs of record. The investor narrative has swung violently over the past year: enthusiasm peaked around the Trump administration's "drone dominance" push, the potential for direct U.S. government equity stakes in domestic drone makers, tariff protection favoring U.S. manufacturers, and the Quaze Technologies acquisition addressing drone power bottlenecks, all of which fueled a sharp May-June rally. That optimism has since reversed hard, with the stock down more than 50% over the trailing year as investors refocus on the company's deeply negative margins, heavy cash burn, and the long, uncertain path from small pilot orders to profitable scale production, leaving the debate centered on whether Red Cat can convert its contract pipeline and domestic-manufacturing positioning into revenue before its capital runway tightens.…
RCAT
Red Cat Holdings, Inc. Common Stock
$4.29
Related headlines
Investment Opinion: Should I buy RCAT Today?
Rating: Hold (speculative, catalyst-dependent). The core thesis is that Red Cat is a legitimate U.S.-centric defense-drone pure play with 109.3% YoY revenue growth and a fortress balance sheet ($325.6 million cash, 0.075 debt-to-equity), but it is not yet investable on fundamentals: gross margin of 16.1% against $41.9 million of quarterly opex produces a -174.6% net margin and -$263.2 million trailing free cash flow, and the stock trades at 23.3x trailing sales. The visible analyst sentiment leans constructive — Needham, HC Wainwright, and Ladenburg Thalmann all carry Buy ratings versus Piper Sandler at Neutral — but with only one contributing EPS/revenue estimate and no published consensus target price, there is no reliable valuation anchor and implied upside cannot be computed from the provided data.\n\nSupporting evidence is genuinely two-sided. On the positive side: revenue grew 109.3% YoY to $20.19 million in Q2 2026 from $9.65 million, gross margin improved to 16.1% from 12.7% in Q1 2026 and 4.2% in the year-ago Q3 2025 quarter, the current ratio is 15.3x with near-zero leverage, and the single forward estimate of $152.1 million revenue and $0.11 EPS implies roughly a 7x ramp and a swing to profitability. On the negative side: trailing PS of 23.3x and price-to-book of 3.85x sit well above mature defense primes in the low-to-mid single digits on sales, the PEG of 0.45 is derived entirely from that unproven forward estimate, trailing PE is -13.2x and EV/EBITDA is -11.5x, and the share count has already risen from ~85.5 million to 136.9 million, with $263.6 million of equity issued in the latest period.\n\nThe biggest risks that would invalidate the thesis are (1) a program-of-record delay or loss that leaves revenue far short of the $152.1 million estimate, (2) gross margins stalling in the mid-teens so the fixed cost base is never covered, and (3) another dilutive raise that transfers the upside to new shareholders. This Hold would upgrade to Buy if gross margin holds above 25% for two consecutive quarters while revenue tracks toward a $150 million annualized run-rate, or if the stock bases above the $3.41 low with a confirmed higher low; it would downgrade to Sell on a decisive break below $3.41 or a quarter where revenue falls sequentially below $15 million. Verdict: the stock is fairly valued to modestly overvalued on trailing metrics and only cheap on a forward estimate that has a single contributor — a speculative position, not a value one.
Sign up to view all
RCAT 12-Month Price Forecast
The forward view is genuinely balanced: the growth is real (109.3% YoY) and the balance sheet ($325.6 million cash, 0.075 debt-to-equity) removes solvency risk, but the economics are not yet working — a 16.1% gross margin cannot support a $41.9 million quarterly opex base, and trailing free cash flow of -$263.2 million means the equity story keeps getting diluted. Valuation is the fulcrum: at 23.3x trailing sales the stock is expensive for a hardware maker, yet the forward ~6.2x PS looks reasonable if the $152.1 million estimate materializes, so the multiple is effectively a bet on a single analyst's ramp assumption. Analyst sentiment leans bullish (three Buy ratings versus one Neutral), but with one contributing estimate and no consensus target, that conviction is directional rather than a valuation anchor. I would upgrade to bullish on two consecutive quarters of gross margin above 25% with revenue annualizing toward $150 million, and downgrade to bearish on a decisive break below the $3.41 low or a quarter with sequential revenue decline below $15 million.
Wall Street consensus
Coverage is extremely thin: only one analyst provides an EPS and revenue estimate in the provided data, and the institutional ratings history shows a small handful of firms — Needham (Buy, reiterated repeatedly through October 2026), HC Wainwright (Buy), Ladenburg Thalmann (Buy), and Piper Sandler (Neutral, October 2026) — with no formal consensus target price or Buy/Hold/Sell distribution available. The lone estimate implies forward EPS of $0.11 and forward revenue of $152.1 million, which, if achieved, would represent a dramatic swing to profitability and a roughly 7x revenue increase; the absence of a published average price target means implied upside cannot be calculated from the provided data. On balance, the visible analyst sentiment leans bullish (three Buy-rated firms versus one Neutral), but the sample is too small to constitute a meaningful consensus.\n\nThe target range is effectively a single point — estimated EPS of $0.11 and revenue of $152.1 million with no low/high dispersion — so no meaningful spread analysis is possible, and the lack of a high/low target range means we cannot infer what bull or bear cases are being priced. What is notable is the divergence between the persistent Buy ratings and the stock's -51.5% one-year decline, suggesting analysts are anchoring on the multi-year defense-drone opportunity and forward revenue ramp while the market discounts execution and dilution risk. With only one contributing estimate, price discovery is likely inefficient and volatility elevated; investors should treat the bullish ratings as directional conviction rather than a reliable valuation anchor, and watch for estimate revisions or new coverage initiations as the key signal for whether the forward revenue ramp is gaining credibility.
Bulls vs Bears: RCAT Investment Factors
The bear case currently holds the stronger evidence: Red Cat is burning $263.2 million in trailing free cash flow, posting a -174.6% net margin, and has lost 51.5% over the past year with a -80.4% peak-to-trough drawdown, all while trading at 23.3x trailing sales. The bull case is real but forward-looking — 109.3% revenue growth, $325.6 million of cash, near-zero debt, and policy tailwinds — and depends on converting a contract pipeline into a ~7x revenue ramp that the single analyst estimate assumes. The single most important tension is whether Red Cat can scale hardware shipments fast enough to lift gross margins from 16.1% toward the 30-40%+ needed to cover its fixed cost base before dilution erodes the equity story; if margins inflect, the forward PS of ~6.2x looks reasonable, but if they stall, the current multiple is unsupportable. Until a technical base forms above the $3.41 low and gross margins show a sustained uptrend, the risk/reward favors patience over accumulation.
Bullish
- Revenue doubling year-over-year: Q2 2026 revenue of $20.19 million grew 109.3% YoY from $9.65 million, and Q1 2026's $15.47 million marked a sequential acceleration. The single analyst estimate implies forward revenue of $152.1 million, roughly a 7x step-up, suggesting the contract pipeline is expected to convert into a durable ramp rather than isolated deliveries.
- Fortress balance sheet, near-zero leverage: Cash stood at $325.6 million at Q2 2026 (up from $167.9 million) after $263.6 million of equity issuance, with a current ratio of 15.3x and debt-to-equity of just 0.075. This gives Red Cat a multi-year runway to fund the production ramp without solvency risk, unlike many small-cap defense peers.
- Analyst sentiment leans bullish despite collapse: Needham, HC Wainwright, and Ladenburg Thalmann all carry Buy ratings (Needham reiterated repeatedly through October 2026), versus only Piper Sandler at Neutral. The lone forward EPS estimate of $0.11 implies a swing to profitability, and the persistence of Buy ratings through a -51.5% one-year decline signals conviction in the multi-year drone opportunity.
- Policy tailwinds favor U.S. drone makers: The Trump administration's 'drone dominance' push, potential direct U.S. government equity stakes in domestic drone manufacturers, and new tariffs on foreign drones (cited in the August 14 Motley Fool piece) all disproportionately benefit a U.S.-centric pure play like Red Cat. The Quaze Technologies acquisition also addresses the drone power bottleneck, potentially unlocking longer-endurance missions.
Bearish
- Deeply negative and deteriorating margins: Q2 2026 gross margin was just 16.1% ($3.26 million gross profit on $20.19 million revenue), far below the 30-40%+ needed to cover a $41.9 million quarterly opex base. The net loss of $35.26 million (-174.6% net margin) and operating loss of $38.65 million show spending vastly outpaces gross profit, and the blended gross margin in the valuation data is only 3.1%.
- Massive cash burn funded by dilution: Trailing free cash flow is -$263.2 million and operating cash flow was -$78.7 million in the latest period, while inventory ballooned by $49.9 million. The share count has climbed from ~85.5 million to 136.9 million, and the -10.6x price-to-cash-flow ratio confirms cash generation, not the balance sheet, is the binding constraint — continued dilution is likely.
- Falling-knife technical profile: The stock is down 51.5% over one year and 50.9% YTD versus the S&P 500's +12.2%, a relative strength of -63.7%, and sits at only ~10% of its 52-week range ($3.41 to mid-$14s). The -80.4% max drawdown from the June peak and -57.8% three-month decline confirm persistent distribution; the 11.4% bounce to $4.50 is a single-day pop, not a trend reversal.
- Valuation still rich for a hardware maker: A 23.3x trailing PS and 3.85x price-to-book sit far above typical defense hardware multiples, and even the forward ~6.2x PS is a premium to mature primes in the low-to-mid single digits. The premium rests entirely on a near-7x revenue ramp that leaves no room for execution error, and the PEG of 0.45 is derived from an unproven profitability assumption.
RCAT Technical Analysis
Red Cat is locked in a severe, sustained downtrend, with the stock down 51.5% over the trailing year and 50.9% year-to-date, a collapse that has erased roughly half its value while the S&P 500 gained 12.2% over the same period (relative strength of -63.7%). At the current $4.50, the stock sits near the very bottom of its 52-week range, which spans roughly $3.41 (the November 5 low) to the mid-$14s reached in early June — meaning the price is trading at only about 10% of its 52-week range, a positioning that signals persistent distribution and a "falling knife" profile rather than a value opportunity until a base forms. The maximum drawdown of -80.4% from the June peak underscores how violent the unwind has been for anyone who bought the momentum.\n\nShort-term momentum remains decisively negative but is showing the first signs of stabilization: the stock is down 22.0% over the past month and 57.8% over three months, both far worse than the S&P's -3.3% and -2.3% respectively, confirming the decline is company-specific rather than market-driven. The one-month decline (-22.0%) is actually less severe than the three-month decline (-57.8%), implying the pace of selling is decelerating, and the most recent session delivered an 11.4% bounce from $4.04 to $4.50 on elevated volume of roughly 7.7 million shares — a potential short-term capitulation-and-rebound signal off the $3.41 low. That said, a single-day pop after a -80% drawdown is far from a trend reversal, and the stock remains below any plausible moving-average structure.\n\nTechnically, the $3.41 November low is the critical support level; a decisive break below it would confirm the downtrend's continuation and likely trigger another leg of momentum-driven selling toward new lows. Resistance is layered: the $4.87-$5.05 area (late-October consolidation) is the first hurdle, with the June highs in the $14-$15 zone representing a distant, structurally significant ceiling that would require a fundamental catalyst to revisit. Beta is not available in the provided data, but the -80.4% max drawdown and the 11.4% single-day move are themselves evidence of extreme volatility — position sizing should assume daily swings of 5-10% and treat this as a speculative, catalyst-dependent holding rather than a core position.
Beta
—
—
Max Drawdown
-80.4%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
-50.5%
Cumulative gain past year
| Period | RCAT Return | S&P 500 |
|---|---|---|
| 1m | -20.4% | -2.4% |
| 3m | -58.1% | -2.3% |
| 6m | -54.8% | +2.8% |
| 1y | -50.5% | +11.3% |
| ytd | -53.2% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RCAT Fundamental Analysis
Revenue is growing but from a very small base and with a lumpy, inconsistent trajectory: Q2 2026 revenue of $20.19 million grew 109.3% year-over-year, a genuine acceleration from the $15.47 million booked in Q1 2026 and a dramatic step-up from the $9.65 million in the year-ago Q2 2025. However, the sequential path is uneven — Q3 2025 (calendar) revenue of $26.24 million was actually higher than the most recent Q2 2026 figure, and the prior-year Q4 2025 quarter collapsed to just $1.63 million, illustrating the order-timing volatility typical of early-stage defense contractors. Product revenue of $19.71 million dwarfs service revenue of $477,000, so the entire growth story rests on hardware shipments; the investment case hinges on whether Red Cat can convert its pipeline into a durable, multi-quarter revenue ramp rather than isolated contract deliveries.\n\nProfitability is deeply negative and, on a gross-margin basis, deteriorating: Q2 2026 gross margin was just 16.1% (gross profit of $3.26 million on $20.19 million revenue), down from 12.7% in Q1 2026 but a sharp compression from the 4.2% and negative -52.3% gross margins seen in prior-year quarters, and well below the 3.1% blended gross margin in the valuation data. The company posted a Q2 2026 net loss of $35.26 million (net margin of -174.6%) and an operating loss of $38.65 million, driven by $41.91 million in operating expenses including $14.22 million of R&D and $27.69 million of SG&A — spending that vastly outpaces gross profit. Trailing EPS of -$0.076 and ROE of -29.3% confirm the company is burning capital to build scale, and with gross margins in the mid-teens, Red Cat is nowhere near the 30-40%+ margins that would be required to cover its fixed cost base.\n\nThe balance sheet is the one genuine bright spot: a current ratio of 15.3x, debt-to-equity of just 0.075, and $325.6 million in cash at the end of Q2 2026 (up from $167.9 million) following $263.6 million of common stock issuance give Red Cat substantial liquidity and near-zero leverage risk. But the cash is being consumed rapidly — trailing free cash flow is -$263.2 million, operating cash flow was -$78.7 million in the latest period, and inventory ballooned by $49.9 million, tying up working capital. The company is funding growth almost entirely through equity dilution rather than internal cash generation, which is why the share count has climbed from roughly 85.5 million to 136.9 million; investors face continued dilution risk unless operating cash flow inflects, and the -$26.3 million FCF figure alongside a -10.6x price-to-cash-flow ratio underscores that cash generation, not the balance sheet, is the binding constraint.
Quarterly Revenue
$20189000.0B
2026-06
Revenue YoY Growth
+109.3%
YoY Comparison
Gross Margin
16.2%
Latest Quarter
Free Cash Flow
$-263215100.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RCAT Overvalued?
Because Red Cat is unprofitable — trailing net income is negative, with a trailing PE of -13.2x and negative EBITDA of -$32.95 million — the PE ratio is not a meaningful primary metric, and the appropriate lead multiple is price-to-sales. On that basis the stock trades at a trailing PS of 23.3x, which is extraordinarily rich for a hardware manufacturer, though the forward picture is dramatically different: the single analyst estimate implies forward EPS of $0.11 and forward revenue of approximately $152.1 million, against which the current $947 million market cap implies a forward PS of roughly 6.2x. That enormous gap between trailing (23.3x) and forward (~6.2x) sales multiples tells you the market is pricing in a near-7x revenue ramp over the next year — an aggressive expectation that leaves little room for execution error.\n\nPeer comparison is hampered by the absence of a formal industry-average valuation dataset, but the context is instructive: Red Cat's 23.3x trailing PS and 3.85x price-to-book sit far above the multiples typically commanded by defense hardware peers, and even the forward ~6.2x PS is a premium to mature defense primes trading in the low-to-mid single digits on sales. The premium is ostensibly justified by growth — 109% YoY revenue growth is exceptional — but with gross margins of only 16.1% and a -174.6% net margin, Red Cat lacks the profitability that would normally underwrite such a multiple. The PEG ratio of 0.45 looks attractive on paper but is derived from a forward EPS estimate that assumes a swing to profitability, making it a fragile signal rather than a reliable value indicator.\n\nHistorically, Red Cat's valuation has been wildly unstable: its PS ratio ranged from roughly 6.4x in early 2023 to a staggering 823x in late 2024 and 581x in Q4 2025, reflecting both the tiny revenue base and the stock's speculative swings. At 23.3x trailing PS today, the stock is near the lower end of its own multi-year band, which could suggest relative value — but the compression largely reflects revenue finally growing into the multiple rather than the stock becoming cheap. The 3.85x price-to-book is similarly mid-range versus historical extremes of 21.9x and 0.75x, reinforcing that valuation here is a function of narrative and contract momentum, not stable fundamentals.
PE
-13.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
37.1x
Industry PE ~37.1x*
EV/EBITDA
-11.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are acute and quantifiable. Red Cat generated only $3.26 million of gross profit in Q2 2026 against $41.9 million of operating expenses, producing a $38.65 million operating loss and a -174.6% net margin, while trailing free cash flow of -$263.2 million and operating cash flow of -$78.7 million show the burn is structural, not one-off. Revenue is highly concentrated in hardware ($19.71 million product vs. $477,000 service) and lumpy — Q4 2025 revenue collapsed to $1.63 million from $26.24 million the prior quarter — so a single delayed program-of-record award could gut a quarter. The $325.6 million cash cushion is real, but with the share count already up from ~85.5 million to 136.9 million, continued equity issuance to fund the ramp is the base case, and inventory growth of $49.9 million ties up working capital precisely when cash discipline matters most. Market and competitive risks center on valuation compression and a crowded field. At 23.3x trailing PS and 3.85x price-to-book, Red Cat trades at a premium to defense hardware peers, and even the forward ~6.2x PS assumes a near-7x revenue ramp that leaves no margin for error; any estimate revision lower would compress the multiple violently, as the -80.4% drawdown already demonstrated. Competition is intensifying — AeroVironment's autonomous systems segment carries a record $1.5 billion backlog, AEVEX raised $320 million in its IPO, and XTEND is pursuing a SPAC listing — all chasing the same $74 billion military drone budget, while Red Cat's 244 employees and small-cap scale ($679.6 million market cap per the identity data) limit its ability to win large programs against primes. Beta is not provided, but the -63.7% one-year relative strength versus the S&P and 11.4% single-day moves confirm the stock is a high-volatility, catalyst-dependent name sensitive to defense-budget headlines and policy shifts. The worst-case scenario is a program-of-record delay or loss combined with a dilutive capital raise: revenue fails to approach the $152.1 million estimate, gross margins stay stuck in the mid-teens, and the market re-rates the stock toward a low-single-digit PS. From the current $4.50, a retest of the November 5 low of $3.41 implies roughly -24%, and a break below that support — with no fundamental catalyst — could extend toward the $2.50-$3.00 zone, a -33% to -44% loss; the -80.4% max drawdown from the June peak shows how far a momentum unwind can run when the narrative breaks.
FAQ
Ranked by severity, the first risk is financial: gross profit of just $3.26 million in Q2 2026 against $41.9 million of operating expenses produced a -174.6% net margin, and trailing free cash flow of -$263.2 million means another dilutive raise is the base case — the share count is already up from ~85.5 million to 136.9 million. Second is execution and revenue concentration: hardware is $19.71 million of $20.19 million in revenue, and quarterly revenue is extremely lumpy (Q4 2025 collapsed to $1.63 million from $26.24 million the prior quarter), so one delayed program-of-record award could gut a quarter. Third is competitive: AeroVironment's autonomous-systems backlog is a record $1.5 billion, AEVEX raised $320 million in its IPO, and XTEND is pursuing a SPAC listing, all chasing the same $74 billion military drone budget against a 244-employee challenger. Fourth is valuation and momentum: at 23.3x trailing PS with a -63.7% one-year relative strength versus the S&P 500 and an -80.4% max drawdown, any estimate revision lower would compress the multiple violently.
The 12-month forecast splits into three scenarios. The base case (50% probability) targets $3.40-$6.00: revenue grows but falls short of the $152.1 million estimate, gross margin grinds up slowly from 16.1%, and the stock oscillates between the $3.41 low and the $5-$6 zone where it traded in September-October 2026. The bull case (25%) targets $9.00-$12.00 and requires a program-of-record award plus gross margin above 25% for two quarters, compressing the forward PS toward 4-5x on realized revenue. The bear case (25%) targets $2.50-$3.40 on a program delay combined with a dilutive raise and margins stuck in the mid-teens. The base case is most likely, and its key assumption is that revenue grows without a transformational award while cash burn is funded by periodic equity issuance — meaning the stock stays catalyst-driven and headline-sensitive rather than re-rating on fundamentals.
The answer depends entirely on which multiple you trust. On trailing metrics RCAT looks expensive: 23.3x trailing PS and 3.85x price-to-book are far above typical defense hardware multiples, and with a trailing PE of -13.2x and EV/EBITDA of -11.5x, earnings-based valuation is meaningless because the company is unprofitable. On the forward estimate, however, the picture flips — $152.1 million of implied revenue against a roughly $947 million market cap gives a forward PS of about 6.2x, approaching mature defense-prime territory, and the PEG of 0.45 looks cheap. That gap is the whole story: the market is paying for a near-7x revenue ramp that has a single contributing analyst and no consensus target. Historically, RCAT's PS has ranged from ~6.4x in early 2023 to 823x in late 2024, so 23.3x is near the low end of its own band — but that reflects revenue growing into the multiple, not the stock becoming cheap. Verdict: fairly valued to modestly overvalued on trailing numbers, and only cheap on an unproven forward estimate.
From a risk/reward perspective, RCAT is a speculative bet rather than a clean buy. The upside case is real: revenue grew 109.3% YoY to $20.19 million, cash of $325.6 million with debt-to-equity of just 0.075 removes solvency risk, and three of four visible analysts (Needham, HC Wainwright, Ladenburg Thalmann) carry Buy ratings, with the lone forward estimate implying $152.1 million revenue and $0.11 EPS. But there is no published consensus target price, so implied upside cannot be computed, and the downside is concrete: from $4.50, a retest of the $3.41 November low is roughly -24%, and a break below could extend to $2.50-$3.00, a -33% to -44% loss. With gross margin at 16.1% against $41.9 million of quarterly opex and trailing free cash flow of -$263.2 million, the equity story keeps getting diluted. It is a reasonable buy only for risk-tolerant investors with a multi-year horizon who size it small and accept that the thesis hinges on margin inflection and a single analyst's ramp assumption.
RCAT is a long-term, thesis-driven holding at best, and a poor candidate for short-term trading unless you are explicitly trading catalysts. The company is early-stage: 244 employees, a $679.6 million market cap, revenue of $20.19 million in the latest quarter, and a path to profitability that the lone estimate puts roughly a year out at $0.11 EPS. Volatility is extreme — an 11.4% single-day move on November 6, a -57.8% three-month decline, and an -80.4% max drawdown from the June peak — so short-term price action is dominated by headlines and momentum rather than fundamentals. There is no dividend (payout ratio of 0, yield of 0), so there is no income component and no reason to hold for yield. Earnings visibility is low given lumpy quarterly revenue and single-analyst coverage. A concrete minimum holding period of 18-24 months is appropriate, sized as a small speculative position, with the thesis reviewed against gross margin progress and the $3.41 support level.